for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Clovis Oncology Inc

CLVS.OQ

Latest Trade

4.74USD

Change

0.00(0.00%)

Volume

6,885,177

Today's Range

4.73

 - 

5.04

52 Week Range

4.73

 - 

34.63

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
4.74
Open
4.80
Volume
6,885,177
3M AVG Volume
74.65
Today's High
5.04
Today's Low
4.73
52 Week High
34.63
52 Week Low
4.73
Shares Out (MIL)
54.66
Market Cap (MIL)
259.07
Forward P/E
-0.63
Dividend (Yield %)
--

Next Event

Q3 2019 Clovis Oncology Inc Earnings Release

Latest Developments

More

Kenneth Griffin Reports 7.0% Passive Stake In Clovis Oncology Inc

Clovis Oncology Announces Pricing Of $250 Mln Of Convertible Senior Notes

Clovis Oncology To Offer $225 Million Of Convertible Senior Notes

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Clovis Oncology Inc

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product Rubraca (rucaparib), an oral small molecule inhibitor of poly adenosine diphosphate (ADP)-ribose polymerase (PARP), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The Company also provides Lucitanib, which is an investigational, oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors one through three (VEGFR1-3), platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors one through three (FGFR1-3).

Industry

Biotechnology & Drugs

Contact Info

5500 Flatiron Pkwy Unit 100

+1.303.6255000

http://www.clovisoncology.com

Executive Leadership

Ginger L. Graham

Chairman of the Board

Patrick J. Mahaffy

President, Chief Executive Officer, Co-Founder, Director

Gillian C. Ivers-Read

Co-Founder, Executive Vice President, Chief Regulatory Officer

Daniel W. Muehl

Executive Vice President of Finance, Principal Accounting Officer and Principal Financial Officer

Paul E. Gross

Executive Vice President, Chief Compliance Officer, General Counsel

Key Stats

2.45 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-9.070

2017

-7.360

2018

-7.070

2019(E)

-7.488
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.17
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-53.84
Return on Equity (TTM)
-47.89

Latest News

Clovis Oncology halts mid-stage bladder cancer trial, shares drop

Clovis Oncology Inc said on Friday it was halting a mid-stage trial testing its lead drug in bladder cancer patients, sending shares down 12 percent.

Clovis Oncology, execs to pay $20 million to settle SEC charges

U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.

BRIEF-Clovis Oncology Reports Q1 Loss Per Share $1.54

* CLOVIS ONCOLOGY ANNOUNCES FIRST QUARTER 2018 OPERATING RESULTS

BRIEF-Clovis Oncology CEO Patrick Mahaffy's 2017 Total Compensation Was $8.7 Million

* CLOVIS ONCOLOGY INC SAYS CEO PATRICK MAHAFFY'S 2017 TOTAL COMPENSATION WAS $8.7 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2KnbE4y) Further company coverage:

BRIEF-Clovis Oncology Announces Pricing Of Public Offerings Of Convertible Senior Notes And Common Stock

* CLOVIS ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERINGS OF CONVERTIBLE SENIOR NOTES AND COMMON STOCK

BRIEF-Clovis Oncology Files Prospectus Supplement Related To Offering $200 Mln Principal Amount Of Convertible Senior Notes

* CLOVIS ONCOLOGY INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING $200 MILLION PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2025 - SEC FILING Source text: (https://bit.ly/2qzin28) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Clovis Oncology Files Prospectus Supplement Related To Offering $100 Mln Of Shares Of Co's Common Stock

* CLOVIS ONCOLOGY INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING $100 MILLION OF SHARES OF CO'S COMMON STOCK - SEC FILING Source text: (https://bit.ly/2HCYkbd) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Clovis Oncology Says SEC Issued 'Wells Notices' To Co & Certain Of Its Officers

* CLOVIS ONCOLOGY SAYS ON APRIL 9 SEC ISSUED 'WELLS NOTICES' TO CO & CERTAIN OF ITS CURRENT AND FORMER OFFICERS - SEC FILING

BRIEF-Clovis Oncology Says Rubraca Approved In U.S. As Maintenance Treatment Of Recurrent Ovarian Cancer

* RUBRACA (RUCAPARIB) APPROVED IN THE U.S. AS MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER

EMA panel for conditional OK to Clovis's ovarian cancer drug

A panel of European Medicines Agency (EMA) has recommended granting conditional marketing approval to Clovis Oncology's drug for ovarian cancer, citing anti-tumour activity.

BRIEF-Clovis Oncology Initiates Early Access Program For Rucaparib

* CLOVIS ONCOLOGY INITIATES EARLY ACCESS PROGRAM FOR RUCAPARIB AS TREATMENT AND AS MAINTENANCE THERAPY IN RECURRENT OVARIAN CANCER IN EUROPE Source text for Eikon: Further company coverage:

BRIEF-EMA Panel Recommends Conditional Approval Of Clovis Oncology Ovarian Cancer Drug Rubraca

* RECOMMENDS APPROVAL OF CLOVIS ONCOLOGY OVARIAN CANCER DRUG RUBRACA

BRIEF-Clovis Oncology Q4 Adjusted Loss Per Share $1.27

* Q4 REVENUE VIEW $20.1 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Clovis Oncology Receives Positive Trend Vote In European Regulatory Review Ovarian Cancer Treatment

* CLOVIS ONCOLOGY RECEIVES POSITIVE TREND VOTE FROM CHMP IN EUROPEAN REGULATORY REVIEW FOR RUCAPARIB OVARIAN CANCER TREATMENT INDICATION

BRIEF-Rucaparib MAA Referred By CHMP To Scientific Advisory Group On Oncology For Review

* RUCAPARIB MAA FOR THE OVARIAN CANCER TREATMENT INDICATION REFERRED BY CHMP TO SCIENTIFIC ADVISORY GROUP ON ONCOLOGY FOR REVIEW EXPECTED IN FEBRUARY 2018

BRIEF-Clovis Announces Priority Review Designation For Rucaparib Supplemental NDA

* CLOVIS ANNOUNCES PRIORITY REVIEW DESIGNATION FOR RUCAPARIB SUPPLEMENTAL NEW DRUG APPLICATION

BRIEF-Clovis Oncology reports Q3 adjusted shr loss of $1.24

* CLOVIS ONCOLOGY ANNOUNCES THIRD QUARTER 2017 OPERATING RESULTS

BRIEF-Clovis Oncology submits supplemental New Drug Application for rucaparib

* Clovis Oncology submits supplemental New Drug Application for rucaparib as maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer

BRIEF-Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet

* Clovis Oncology's Rucaparib Ariel3 study data published in The Lancet

BRIEF-Clovis Oncology Q2 loss per share $3.88

* Clovis Oncology announces second quarter 2017 operating results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up